{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:51:09Z","timestamp":1779907869896,"version":"3.53.1"},"reference-count":202,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2021YFE0103100"],"award-info":[{"award-number":["2021YFE0103100"]}]},{"name":"National Key Research and Development Program of China","award":["8201101172"],"award-info":[{"award-number":["8201101172"]}]},{"name":"National Key Research and Development Program of China","award":["81925035"],"award-info":[{"award-number":["81925035"]}]},{"name":"National Key Research and Development Program of China","award":["81521005"],"award-info":[{"award-number":["81521005"]}]},{"name":"National Key Research and Development Program of China","award":["19431903100"],"award-info":[{"award-number":["19431903100"]}]},{"name":"National Key Research and Development Program of China","award":["18430740800"],"award-info":[{"award-number":["18430740800"]}]},{"name":"National Nature Science Foundation of China","award":["2021YFE0103100"],"award-info":[{"award-number":["2021YFE0103100"]}]},{"name":"National Nature Science Foundation of China","award":["8201101172"],"award-info":[{"award-number":["8201101172"]}]},{"name":"National Nature Science Foundation of China","award":["81925035"],"award-info":[{"award-number":["81925035"]}]},{"name":"National Nature Science Foundation of China","award":["81521005"],"award-info":[{"award-number":["81521005"]}]},{"name":"National Nature Science Foundation of China","award":["19431903100"],"award-info":[{"award-number":["19431903100"]}]},{"name":"National Nature Science Foundation of China","award":["18430740800"],"award-info":[{"award-number":["18430740800"]}]},{"name":"Shanghai Sci-Tech Innovation Initiative","award":["2021YFE0103100"],"award-info":[{"award-number":["2021YFE0103100"]}]},{"name":"Shanghai Sci-Tech Innovation Initiative","award":["8201101172"],"award-info":[{"award-number":["8201101172"]}]},{"name":"Shanghai Sci-Tech Innovation Initiative","award":["81925035"],"award-info":[{"award-number":["81925035"]}]},{"name":"Shanghai Sci-Tech Innovation Initiative","award":["81521005"],"award-info":[{"award-number":["81521005"]}]},{"name":"Shanghai Sci-Tech Innovation Initiative","award":["19431903100"],"award-info":[{"award-number":["19431903100"]}]},{"name":"Shanghai Sci-Tech Innovation Initiative","award":["18430740800"],"award-info":[{"award-number":["18430740800"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Cancer is one of the most serious human diseases, causing millions of deaths worldwide annually, and, therefore, it is one of the most investigated research disciplines. Developing efficient anticancer tools includes studying the effects of different natural enzymes of plant and microbial origin on tumor cells. The development of various smart delivery systems based on enzyme drugs has been conducted for more than two decades. Some of these delivery systems have been developed to the point that they have reached clinical stages, and a few have even found application in selected cancer treatments. Various biological, chemical, and physical approaches have been utilized to enhance their efficiencies by improving their delivery and targeting. In this paper, we review advanced delivery systems for enzyme drugs for use in cancer therapy. Their structure-based functions, mechanisms of action, fused forms with other peptides in terms of targeting and penetration, and other main results from in vivo and clinical studies of these advanced delivery systems are highlighted.<\/jats:p>","DOI":"10.3390\/molecules27123836","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T01:39:54Z","timestamp":1655257194000},"page":"3836","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Advances on Delivery of Cytotoxic Enzymes as Anticancer Agents"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5700-1061","authenticated-orcid":false,"given":"Akmal M.","family":"Asrorov","sequence":"first","affiliation":[{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"},{"name":"Institute of Bioorganic Chemistry, Uzbekistan Academy of Sciences, Tashkent 100125, Uzbekistan"},{"name":"Science Department, Ajou University in Tashkent, Tashkent 100204, Uzbekistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahtiyor","family":"Muhitdinov","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"},{"name":"Institute of Bioorganic Chemistry, Uzbekistan Academy of Sciences, Tashkent 100125, Uzbekistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Tu","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharafitdin","family":"Mirzaakhmedov","sequence":"additional","affiliation":[{"name":"Institute of Bioorganic Chemistry, Uzbekistan Academy of Sciences, Tashkent 100125, Uzbekistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhuo","family":"Huang","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"},{"name":"Zhongshan Institute for Drug Discovery, Chinese Academy of Sciences, Zhongshan 528437, China"},{"name":"National Medical Products Administration, Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.2174\/1381612820666140826153913","article-title":"Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: A lethal cocktail with tumor specific efficacy","volume":"20","author":"Weng","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1021\/acsptsci.9b00087","article-title":"Advances on Tumor-Targeting Delivery of Cytotoxic Proteins","volume":"3","author":"Asrorov","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s40880-015-0030-x","article-title":"Anti-tumor activities and apoptotic mechanism of ribosome-inactivating proteins","volume":"34","author":"Zeng","year":"2015","journal-title":"Chin. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rust, A., Partridge, L.J., Davletov, B., and Hautbergue, G.M. (2017). The Use of Plant-Derived Ribosome Inactivating Proteins in Immunotoxin Development: Past, Present and Future Generations. Toxins, 9.","DOI":"10.3390\/toxins9110344"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1359-6446(05)03394-5","article-title":"Peroxidases: A role in the metabolism and side effects of drugs","volume":"10","author":"Tafazoli","year":"2005","journal-title":"Drug Discov. Today"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2000110","DOI":"10.1002\/adtp.202000110","article-title":"Glucose Oxidase-Related Cancer Therapies","volume":"3","author":"Wang","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1054\/mehy.2000.1406","article-title":"Hydrogen peroxide: A potent cytotoxic agent effective in causing cellular damage and used in the possible treatment for certain tumours","volume":"57","author":"Symons","year":"2001","journal-title":"Med. Hypotheses"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3389\/fonc.2019.00522","article-title":"Potential Use of Gluconate in Cancer Therapy","volume":"9","author":"Mycielska","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/0976-500X.184769","article-title":"L-asparaginase in the treatment of patients with acute lymphoblastic leukemia","volume":"7","author":"Egler","year":"2016","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2015.01.002","article-title":"Recent developments in L-asparaginase discovery and its potential as anticancer agent","volume":"100","author":"Shrivastava","year":"2016","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1517\/14656566.8.12.1977","article-title":"PEG-asparaginase","volume":"8","author":"Fu","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1128\/CMR.8.1.34","article-title":"The family of bacterial ADP-ribosylating exotoxins","volume":"8","author":"Krueger","year":"1995","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijmm.2008.08.003","article-title":"Pseudomonas exotoxin A: From virulence factor to anti-cancer agent","volume":"299","author":"Wolf","year":"2009","journal-title":"Int. J. Med. Microbiol. IJMM"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"24647","DOI":"10.1074\/jbc.M113.488783","article-title":"ADP-ribosylation of translation elongation factor 2 by diphtheria toxin in yeast inhibits translation and cell separation","volume":"288","author":"Mateyak","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1166\/jnn.2015.9271","article-title":"Effect of Radix Trichosanthis and Trichosanthin on Hepatitis B Virus in HepG2.2.15 Cells","volume":"15","author":"Wen","year":"2015","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.lfs.2006.03.047","article-title":"Trichosanthin suppresses the elevation of p38 MAPK, and Bcl-2 induced by HSV-1 infection in Vero cells","volume":"79","author":"Huang","year":"2006","journal-title":"Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bbrc.2009.04.124","article-title":"A novel sorting strategy of trichosanthin for hijacking human immunodeficiency virus type 1","volume":"384","author":"Zhao","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/abbs\/gmp111","article-title":"The anti-viral protein of trichosanthin penetrates into human immunodeficiency virus type 1","volume":"42","author":"Zhao","year":"2010","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1084\/jem.190.1.101","article-title":"Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors","volume":"190","author":"Zhao","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s11033-008-9352-y","article-title":"Induced apoptotic action of recombinant trichosanthin in human stomach adenocarcinoma MCG803 cells","volume":"36","author":"Xu","year":"2009","journal-title":"Mol. Biol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1038\/sj.onc.1207116","article-title":"Control of apoptosis by p53","volume":"22","author":"Fridman","year":"2003","journal-title":"Oncogene"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Al Bitar, S., and Gali-Muhtasib, H. (2019). The Role of the Cyclin Dependent Kinase Inhibitor p21(cip1\/waf1) in Targeting Cancer: Molecular Mechanisms and Novel Therapeutics. Cancers, 11.","DOI":"10.3390\/cancers11101475"},{"key":"ref_23","first-page":"675","article-title":"Effect of trichosanthin on apoptosis and telomerase activity of nasopharyngeal carcinomas in nude mice","volume":"18","author":"Kang","year":"2013","journal-title":"J. BUON"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.bbagen.2007.04.007","article-title":"Trichosanthin induced apoptosis in HL-60 cells via mitochondrial and endoplasmic reticulum stress signaling pathways","volume":"1770","author":"Li","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.biopha.2014.10.027","article-title":"Smac is another pathway in the anti-tumour activity of Trichosanthin and reverses Trichosanthin resistance in CaSki cervical cancer cells","volume":"69","author":"Cui","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3892\/mmr.2012.994","article-title":"Trichosanthin inhibits DNA methyltransferase and restores methylation-silenced gene expression in human cervical cancer cells","volume":"6","author":"Huang","year":"2012","journal-title":"Mol. Med. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40659-016-0081-8","article-title":"The anti-cancerous activity of recombinant trichosanthin on prostate cancer cell PC3","volume":"49","author":"Li","year":"2016","journal-title":"Biol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/bs.acc.2015.12.003","article-title":"Apoptosis Markers in Breast Cancer Therapy","volume":"74","author":"Kadam","year":"2016","journal-title":"Adv. Clin. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Shi, W.W., Wong, K.B., and Shaw, P.C. (2018). Structural and Functional Investigation and Pharmacological Mechanism of Trichosanthin, a Type 1 Ribosome-Inactivating Protein. Toxins, 10.","DOI":"10.3390\/toxins10080335"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0300-483X(02)00746-1","article-title":"Receptor-mediated endocytosis of trichosanthin in choriocarcinoma cells","volume":"186","author":"Chan","year":"2003","journal-title":"Toxicology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.bbrc.2009.12.006","article-title":"Low-density lipoprotein receptor-related protein 1 is an essential receptor for trichosanthin in 2 choriocarcinoma cell lines","volume":"391","author":"Jiao","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.3892\/or.2015.4290","article-title":"Trichosanthin suppresses the proliferation of glioma cells by inhibiting LGR5 expression and the Wnt\/beta-catenin signaling pathway","volume":"34","author":"Miao","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.semcdb.2010.09.004","article-title":"Wnt signaling in stem and cancer stem cells","volume":"21","author":"Wend","year":"2010","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/cmi.2011.12","article-title":"Trichosanthin enhances anti-tumor immune response in a murine Lewis lung cancer model by boosting the interaction between TSLC1 and CRTAM","volume":"8","author":"Cai","year":"2011","journal-title":"Cell Mol. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-3083.2010.02372.x","article-title":"A role for trichosanthin in the expansion of CD4CD25 regulatory T cells","volume":"71","author":"Wang","year":"2010","journal-title":"Scand. J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s11033-010-0432-4","article-title":"Increase of cytosolic calcium induced by trichosanthin suppresses cAMP\/PKC levels through the inhibition of adenylyl cyclase activity in HeLa cells","volume":"38","author":"Jiang","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10565-008-9102-x","article-title":"Trichosanthin suppresses HeLa cell proliferation through inhibition of the PKC\/MAPK signaling pathway","volume":"25","author":"Wang","year":"2009","journal-title":"Cell Biol. Toxicol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Fang, E.F., Zhang, C.Z., Zhang, L., Wong, J.H., Chan, Y.S., Pan, W.L., Dan, X.L., Yin, C.M., Cho, C.H., and Ng, T.B. (2012). Trichosanthin inhibits breast cancer cell proliferation in both cell lines and nude mice by promotion of apoptosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041592"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00280-013-2096-y","article-title":"Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: A mini review","volume":"71","author":"Sha","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.addr.2012.11.007","article-title":"Curb challenges of the \u201cTrojan Horse\u201d approach: Smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery","volume":"65","author":"Huang","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.biomaterials.2016.11.033","article-title":"Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature","volume":"116","author":"Chen","year":"2017","journal-title":"Biomaterials"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1021\/acs.molpharmaceut.6b00987","article-title":"Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance","volume":"14","author":"Chen","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.7150\/thno.20578","article-title":"Glioma Dual-Targeting Nanohybrid Protein Toxin Constructed by Intein-Mediated Site-Specific Ligation for Multistage Booster Delivery","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"26648","DOI":"10.1021\/acsami.7b05292","article-title":"Co-Delivery of Trichosanthin and Albendazole by Nano-Self-Assembly for Overcoming Tumor Multidrug-Resistance and Metastasis","volume":"9","author":"Tang","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1021\/acsnano.6b04268","article-title":"Blood-Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy","volume":"10","author":"Lin","year":"2016","journal-title":"ACS Nano"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1039\/C8NR08951E","article-title":"Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy","volume":"11","author":"Chang","year":"2019","journal-title":"Nanoscale"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/jir.1995.15.547","article-title":"Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum","volume":"15","author":"Rosenblum","year":"1995","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/B978-0-12-416039-2.00008-2","article-title":"Cell-targeting fusion constructs containing recombinant gelonin","volume":"502","author":"Lyu","year":"2012","journal-title":"Methods Enzymol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1016\/S0021-9258(18)43667-8","article-title":"Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A","volume":"255","author":"Stirpe","year":"1980","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0378-1119(93)90097-M","article-title":"Cloning and expression of a gene encoding gelonin, a ribosome-inactivating protein from Gelonium multiflorum","volume":"134","author":"Nolan","year":"1993","journal-title":"Gene"},{"key":"ref_51","first-page":"2690","article-title":"PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study","volume":"32","author":"Shin","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2174\/1389450118666170302094758","article-title":"Improved Protein Toxin Delivery Based on ATTEMPTS Systems","volume":"19","author":"Chen","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7150\/ntno.18292","article-title":"Heparin-Regulated Prodrug-Type Macromolecular Theranostic Systems for Cancer Therapy","volume":"1","author":"Wang","year":"2017","journal-title":"Nanotheranostics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/jbm.a.35188","article-title":"Recombinant TAT-gelonin fusion toxin: Synthesis and characterization of heparin\/protamine-regulated cell transduction","volume":"103","author":"Shin","year":"2015","journal-title":"J. Biomed. Mater. Res. A"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/jbm.a.34859","article-title":"Cell-penetrating peptides: Achievements and challenges in application for cancer treatment","volume":"102","author":"Shin","year":"2014","journal-title":"J. Biomed. Mater. Res. A"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1073\/pnas.122157899","article-title":"In vitro and in vivo studies of a VEGF121\/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors","volume":"99","author":"Veenendaal","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2018.09.005","article-title":"Light-enhanced VEGF121\/rGel: A tumor targeted modality with vascular and immune-mediated efficacy","volume":"288","author":"Weyergang","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1007\/s11095-016-1959-4","article-title":"Preparation and Characterization of Gelonin-Melittin Fusion Biotoxin for Synergistically Enhanced Anti-Tumor Activity","volume":"33","author":"Shin","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1038\/onc.2015.15","article-title":"Design of an EGFR-targeting toxin for photochemical delivery: In vitro and in vivo selectivity and efficacy","volume":"34","author":"Berstad","year":"2015","journal-title":"Oncogene"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1158\/0008-5472.CAN-05-3387","article-title":"Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors","volume":"66","author":"Amin","year":"2006","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"12436","DOI":"10.18632\/oncotarget.3814","article-title":"Photochemical activation of MH3-B1\/rGel: A HER2-targeted treatment approach for ovarian cancer","volume":"6","author":"Berstad","year":"2015","journal-title":"Oncotarget"},{"key":"ref_62","first-page":"1180","article-title":"Photochemical internalization: A novel technology for delivery of macromolecules into cytosol","volume":"59","author":"Berg","year":"1999","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/ijc.29510","article-title":"Enhancing the efficacy of cytotoxic agents for cancer therapy using photochemical internalisation","volume":"138","author":"Moore","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s12272-017-0953-7","article-title":"Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy","volume":"40","author":"Ham","year":"2017","journal-title":"Arch. Pharm. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2017.03.072","article-title":"Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment","volume":"524","author":"Shin","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/aps.2017.20","article-title":"Molecular tumor targeting of gelonin by fusion with F3 peptide","volume":"38","author":"Ham","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1080\/1061186X.2018.1516221","article-title":"Genetic engineering and characterisation of chlorotoxin-fused gelonin for enhanced glioblastoma therapy","volume":"27","author":"Park","year":"2019","journal-title":"J. Drug Target."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1182\/blood-2006-08-042424","article-title":"The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells","volume":"109","author":"Nimmanapalli","year":"2007","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bcp.2010.07.017","article-title":"The rGel\/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma","volume":"80","author":"Lyu","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1593\/neo.91960","article-title":"The rGel\/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo","volume":"12","author":"Lyu","year":"2010","journal-title":"Neoplasia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1535-7163.MCT-06-0254","article-title":"The rGel\/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA","volume":"6","author":"Lyu","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"8987","DOI":"10.1158\/0008-5472.CAN-09-2693","article-title":"Construction and characterization of novel, recombinant immunotoxins targeting the Her2\/neu oncogene product: In vitro and in vivo studies","volume":"69","author":"Cao","year":"2009","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"35102","DOI":"10.1074\/jbc.M305411200","article-title":"Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin","volume":"278","author":"Provoda","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jconrel.2013.08.016","article-title":"Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity","volume":"172","author":"Shin","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4155\/pbp.13.23","article-title":"Production and purification of the multifunctional enzyme horseradish peroxidase","volume":"1","author":"Spadiut","year":"2013","journal-title":"Pharm. Bioprocess."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0006-2952(00)00498-6","article-title":"Oxidative activation of indole-3-acetic acids to cytotoxic species- a potential new role for plant auxins in cancer therapy","volume":"61","author":"Folkes","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.febslet.2006.01.073","article-title":"Hydrogen peroxide is a mediator of indole-3-acetic acid\/horseradish peroxidase-induced apoptosis","volume":"580","author":"Kim","year":"2006","journal-title":"FEBS Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.redox.2016.10.010","article-title":"Tumor cells have decreased ability to metabolize H2O2: Implications for pharmacological ascorbate in cancer therapy","volume":"10","author":"Doskey","year":"2016","journal-title":"Redox Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"80093","DOI":"10.18632\/oncotarget.20278","article-title":"Glutathione peroxidases as oncotargets","volume":"8","author":"Jiao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nature07733","article-title":"Association of reactive oxygen species levels and radioresistance in cancer stem cells","volume":"458","author":"Diehn","year":"2009","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/ijc.25944","article-title":"Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells","volume":"129","author":"Ye","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Kennedy, L., Sandhu, J.K., Harper, M.E., and Cuperlovic-Culf, M. (2020). Role of Glutathione in Cancer: From Mechanisms to Therapies. Biomolecules, 10.","DOI":"10.3390\/biom10101429"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101391","DOI":"10.1016\/j.redox.2019.101391","article-title":"Glutathione peroxidase-1 regulates adhesion and metastasis of triple-negative breast cancer cells via FAK signaling","volume":"29","author":"Lee","year":"2020","journal-title":"Redox Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.cgt.7700258","article-title":"Development of a novel enzyme\/prodrug combination for gene therapy of cancer: Horseradish peroxidase\/indole-3-acetic acid","volume":"7","author":"Greco","year":"2000","journal-title":"Cancer Gene Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cam4.668","article-title":"Recombinant horseradish peroxidase variants for targeted cancer treatment","volume":"5","author":"Bonifert","year":"2016","journal-title":"Cancer Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.procbio.2020.08.007","article-title":"Immobilization and characterization of horseradish peroxidase into chitosan and chitosan\/PEG nanoparticles: A comparative study","volume":"98","author":"Melo","year":"2020","journal-title":"Process Biochem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10614","DOI":"10.1039\/C8CC06130K","article-title":"An anthraquinone-enzyme-peptide hybrid as a photo-switchable enzyme","volume":"54","author":"Sotokawa","year":"2018","journal-title":"Chem. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.biotechadv.2009.04.003","article-title":"Glucose oxidase\u2014An overview","volume":"27","author":"Bankar","year":"2009","journal-title":"Biotechnol Adv."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.3390\/s8095637","article-title":"Immobilization of the Enzyme Glucose Oxidase on Both Bulk and Porous SiO2 Surfaces","volume":"8","author":"Libertino","year":"2008","journal-title":"Sensors"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bioelechem.2019.04.015","article-title":"Engineering glucose oxidase for bioelectrochemical applications","volume":"128","author":"Mano","year":"2019","journal-title":"Bioelectrochemistry"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00253-008-1407-4","article-title":"Glucose oxidase: Natural occurrence, function, properties and industrial applications","volume":"78","author":"Wong","year":"2008","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Zhao, L., Wang, L., Zhang, Y., Xiao, S., Bi, F., Zhao, J., Gai, G., and Ding, J. (2017). Glucose Oxidase-Based Glucose-Sensitive Drug Delivery for Diabetes Treatment. Polymers, 9.","DOI":"10.3390\/polym9070255"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e1902004","DOI":"10.1002\/adma.201902004","article-title":"Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation","volume":"32","author":"Wang","year":"2020","journal-title":"Adv. Mater."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1021\/acsnano.9b06395","article-title":"Glucose-Responsive Nanoparticles for Rapid and Extended Self-Regulated Insulin Delivery","volume":"14","author":"Volpatti","year":"2020","journal-title":"ACS Nano"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e2003130","DOI":"10.1002\/adma.202003130","article-title":"Glucose Oxidase-Instructed Multimodal Synergistic Cancer Therapy","volume":"32","author":"Fu","year":"2020","journal-title":"Adv. Mater."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/09553002.2019.1589653","article-title":"The Warburg effect: Essential part of metabolic reprogramming and central contributor to cancer progression","volume":"95","author":"Vaupel","year":"2019","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e1903895","DOI":"10.1002\/smll.201903895","article-title":"Recent Advances in Glucose-Oxidase-Based Nanocomposites for Tumor Therapy","volume":"15","author":"Wang","year":"2019","journal-title":"Small"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.1039\/C7CS00891K","article-title":"Catalytic chemistry of glucose oxidase in cancer diagnosis and treatment","volume":"47","author":"Fu","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"23528","DOI":"10.1021\/acsami.7b06814","article-title":"Glucose Oxidase-Polymer Nanogels for Synergistic Cancer-Starving and Oxidation Therapy","volume":"9","author":"Zhao","year":"2017","journal-title":"ACS Appl Mater. Interfaces"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e1805919","DOI":"10.1002\/adma.201805919","article-title":"Nanocatalysts-Augmented and Photothermal-Enhanced Tumor-Specific Sequential Nanocatalytic Therapy in Both NIR-I and NIR-II Biowindows","volume":"31","author":"Feng","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"7609","DOI":"10.1021\/acs.nanolett.8b03178","article-title":"An Adenosine Triphosphate-Responsive Autocatalytic Fenton Nanoparticle for Tumor Ablation with Self-Supplied H2O2 and Acceleration of Fe(III)\/Fe(II) Conversion","volume":"18","author":"Zhang","year":"2018","journal-title":"Nano Lett."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"101274","DOI":"10.1016\/j.isci.2020.101274","article-title":"Tumor Microenvironment-Activated Degradable Multifunctional Nanoreactor for Synergistic Cancer Therapy and Glucose SERS Feedback","volume":"23","author":"Sun","year":"2020","journal-title":"iScience"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"120106","DOI":"10.1016\/j.biomaterials.2020.120106","article-title":"Biodegradable Poly(gamma-glutamic acid)@glucose oxidase@carbon dot nanoparticles for simultaneous multimodal imaging and synergetic cancer therapy","volume":"252","author":"Zhang","year":"2020","journal-title":"Biomaterials"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.7150\/thno.40439","article-title":"Glucose Oxidase-Instructed Traceable Self-Oxygenation\/Hyperthermia Dually Enhanced Cancer Starvation Therapy","volume":"10","author":"He","year":"2020","journal-title":"Theranostics"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2007.02.027","article-title":"Immobilization and bioactivity of glucose oxidase in hydrogel microspheres formulated by an emulsification-internal gelation-adsorption-polyelectrolyte coating method","volume":"339","author":"Liu","year":"2007","journal-title":"Int. J. Pharm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.colsurfb.2015.04.002","article-title":"Optimizing the design and in vitro evaluation of bioreactive glucose oxidase-microspheres for enhanced cytotoxicity against multidrug resistant breast cancer cells","volume":"130","author":"Cheng","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.2147\/IJN.S195900","article-title":"Glucose-responsive mesoporous silica nanoparticles to generation of hydrogen peroxide for synergistic cancer starvation and chemistry therapy","volume":"14","author":"Du","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e1900183","DOI":"10.1002\/mabi.201900183","article-title":"Intracellular Delivery of Glucose Oxidase for Enhanced Cytotoxicity toward PSMA-Expressing Prostate Cancer Cells","volume":"19","author":"Flynn","year":"2019","journal-title":"Macromol. Biosci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12274-020-3071-7","article-title":"ATP-responsive hollow nanocapsules for DOX\/GOx delivery to enable tumor inhibition with suppressed P-glycoprotein","volume":"14","author":"Zhu","year":"2021","journal-title":"Nano Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1182\/blood-2013-10-535112","article-title":"The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells","volume":"123","author":"Chan","year":"2014","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/157489212798358001","article-title":"Expanding targets for a metabolic therapy of cancer: L-asparaginase","volume":"7","author":"Covini","year":"2012","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fbioe.2018.00212","article-title":"Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles","volume":"6","author":"Brumano","year":"2018","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cmet.2017.12.006","article-title":"As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid","volume":"27","author":"Pavlova","year":"2018","journal-title":"Cell Metab."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"102076","DOI":"10.1016\/j.ceca.2019.102076","article-title":"L-asparaginase-induced apoptosis in ALL cells involves IP3 receptor signaling","volume":"83","author":"Vervliet","year":"2019","journal-title":"Cell Calcium"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/1097-0142(197002)25:2<306::AID-CNCR2820250206>3.0.CO;2-H","article-title":"coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children","volume":"25","author":"Tallal","year":"1970","journal-title":"Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"101973","DOI":"10.1016\/j.isci.2020.101973","article-title":"Metagenomic discovery and functional validation of L-asparaginases with anti-leukemic effect from the Caspian Sea","volume":"24","author":"Sobat","year":"2021","journal-title":"iScience"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.biortech.2017.05.057","article-title":"Genetic and metabolic engineering approaches for the production and delivery of L-asparaginases: An overview","volume":"245 Pt B","author":"Vidya","year":"2017","journal-title":"Bioresour. Technol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Nunes, J.C.F., Cristovao, R.O., Freire, M.G., Santos-Ebinuma, V.C., Faria, J.L., Silva, C.G., and Tavares, A.P.M. (2020). Recent Strategies and Applications for l-Asparaginase Confinement. Molecules, 25.","DOI":"10.3390\/molecules25245827"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/j.1742-4658.2009.06910.x","article-title":"Engineering thermal stability of L-asparaginase by in vitro directed evolution","volume":"276","author":"Kotzia","year":"2009","journal-title":"FEBS J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1074\/jbc.M113.486530","article-title":"Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: Evaluation of immunogenicity in mice","volume":"289","author":"Mehta","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1042\/BJ20061708","article-title":"Tailoring structure-function properties of L-asparaginase: Engineering resistance to trypsin cleavage","volume":"404","author":"Kotzia","year":"2007","journal-title":"Biochem. J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e000858","DOI":"10.1136\/esmoopen-2020-000858","article-title":"Managing toxicities with asparaginase-based therapies in adult ALL: Summary of an ESMO Open-Cancer Horizons roundtable discussion","volume":"5","author":"Burke","year":"2020","journal-title":"ESMO Open"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jconrel.2008.06.017","article-title":"PTD-modified ATTEMPTS system for enhanced asparaginase therapy: A proof-of-concept investigation","volume":"130","author":"Kwon","year":"2008","journal-title":"J. Control. Release"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0378-5173(93)90213-Y","article-title":"Liposomal l-asparaginase: In vitro evaluation","volume":"96","author":"Cruz","year":"1993","journal-title":"Int. J. Pharm."},{"key":"ref_125","first-page":"112","article-title":"Design and evaluation of liposomal delivery system for L-Asparaginese","volume":"2","author":"De","year":"2012","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.colsurfb.2016.03.046","article-title":"Chitosan-modified lipid nanovesicles for efficient systemic delivery of l-asparaginase","volume":"143","author":"Wan","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/1556-276X-9-340","article-title":"Preparation and nanoencapsulation of l-asparaginase II in chitosan-tripolyphosphate nanoparticles and in vitro release study","volume":"9","author":"Bahreini","year":"2014","journal-title":"Nanoscale Res. Lett."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"101417","DOI":"10.1016\/j.jddst.2019.101417","article-title":"Synthesis, characterization and anticancer activity of \u03b2-cyclodextrin-Asparaginase nanobiocomposite on prostate and lymphoma cancer cells","volume":"55","author":"Baskar","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"101689","DOI":"10.1016\/j.jddst.2020.101689","article-title":"Anticancer activity of gelatin-asparaginase nanobiocomposite against cervical and brain cancer cell lines","volume":"57","author":"Baskar","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1039\/b925747k","article-title":"Self-assembly hollow nanosphere for enzyme encapsulation","volume":"6","author":"Ha","year":"2010","journal-title":"Soft Matter."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jsps.2020.04.014","article-title":"Design of expert guided investigation of native L-asparaginase encapsulated long-acting cross-linker-free poly (lactic-co-glycolic) acid nanoformulation in an Ehrlich ascites tumor model","volume":"28","author":"Singh","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3534807","DOI":"10.1155\/2019\/3534807","article-title":"Nanoliposomal L-Asparaginase and Its Antitumor Activities in Lewis Lung Carcinoma Tumor-Induced BALB\/c Mice","volume":"2019","author":"Do","year":"2019","journal-title":"Adv. Mater. Sci. Eng."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1021\/acscentsci.8b00168","article-title":"Confinement of Therapeutic Enzymes in Selectively Permeable Polymer Vesicles by Polymerization-Induced Self-Assembly (PISA) Reduces Antibody Binding and Proteolytic Susceptibility","volume":"4","author":"Blackman","year":"2018","journal-title":"ACS Cent. Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"15007","DOI":"10.1038\/mto.2015.7","article-title":"L-Asparaginase delivered by Salmonella typhimurium suppresses solid tumors","volume":"2","author":"Kim","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"8693","DOI":"10.1039\/D1NR01127H","article-title":"Biomimetic camouflage delivery strategies for cancer therapy","volume":"13","author":"Asrorov","year":"2021","journal-title":"Nanoscale"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1182\/blood.V118.21.4252.4252","article-title":"L-Asparaginase Loaded Red Blood Cells: From Prescription to Injection","volume":"118","author":"Bailly","year":"2011","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1016\/j.jmrt.2020.10.021","article-title":"Immobilization of l-asparaginase on gold nanoparticles for novel drug delivery approach as anti-cancer agent against human breast carcinoma cells","volume":"9","author":"Sulaiman","year":"2020","journal-title":"J. Mater. Res. Technol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jddst.2018.02.007","article-title":"Gold nanoparticle mediated delivery of fungal asparaginase against cancer cells","volume":"44","author":"Baskar","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.msec.2018.08.051","article-title":"Synthesis, characterization and synergistic activity of cerium-selenium nanobiocomposite of fungal l-asparaginase against lung cancer","volume":"93","author":"Baskar","year":"2018","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"21346","DOI":"10.1021\/am5063025","article-title":"Poly(2-vinyl-4,4-dimethylazlactone)-functionalized magnetic nanoparticles as carriers for enzyme immobilization and its application","volume":"6","author":"Mu","year":"2014","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1586\/eri.09.42","article-title":"Microbial Toxins: Current Research and Future Trends","volume":"7","author":"Mohamadzadeh","year":"2009","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_142","first-page":"7","article-title":"Recent advances in microbial toxin-related strategies to combat cancer","volume":"7","author":"Sharma","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1128\/iai.9.1.113-118.1974","article-title":"Purification and characterization of Pseudomonas aeruginosa exotoxin","volume":"9","author":"Callahan","year":"1974","journal-title":"Infect. Immun."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1021\/bc00013a010","article-title":"Properties of chimeric toxins with two recognition domains: Interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin","volume":"3","author":"Kreitman","year":"1992","journal-title":"Bioconj. Chem."},{"key":"ref_145","first-page":"693","article-title":"Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2)","volume":"6","author":"Robbins","year":"2000","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"7610","DOI":"10.1016\/S0021-9258(17)37331-3","article-title":"Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner","volume":"269","author":"Kuan","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jmb.2013.11.002","article-title":"Structural complementation of the catalytic domain of pseudomonas exotoxin A","volume":"426","author":"Boland","year":"2014","journal-title":"J. Mol. Biol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"El-Behaedi, S., Landsman, R., Rudloff, M., Kolyvas, E., Albalawy, R., Zhang, X., Bera, T., Collins, K., Kozlov, S., and Alewine, C. (2018). Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors. Toxins, 10.","DOI":"10.3390\/toxins10110447"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1067\/msy.2003.112","article-title":"CD8+ T-cell mediated tumor protection by Pseudomonas exotoxin fused to ovalbumin in C57BL\/6 mice","volume":"133","author":"Becerra","year":"2003","journal-title":"Surgery"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.carbpol.2010.10.051","article-title":"Chitosan microparticles loaded with exotoxin A subunit antigen for intranasal vaccination against Pseudomonas aeruginosa: An in vitro study","volume":"83","author":"Taranejoo","year":"2011","journal-title":"Carbohydr. Polym."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.toxicon.2010.07.007","article-title":"Pseudomonas exotoxin kills Drosophila S2 cells via apoptosis","volume":"56","author":"Sharma","year":"2010","journal-title":"Toxicon"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"24847","DOI":"10.1016\/S0021-9258(19)74542-6","article-title":"Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain","volume":"268","author":"Leamon","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.V90.1.252.252_252_259","article-title":"Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells","volume":"90","author":"Kreitman","year":"1997","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/07357907.2019.1655761","article-title":"Preparation of Diphtheria and Pseudomonas Exotoxin A Immunotoxins and Evaluation of Their Cytotoxicity Effect on SK-BR-3, BT-474, and MDA-MB-231 Breast Cancer Cell Lines","volume":"37","author":"Amoozadeh","year":"2019","journal-title":"Cancer Investig."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jim.2015.02.002","article-title":"The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein \u03b1-Fc-ETA\u2019 enables screening of antibodies for immunotoxin development","volume":"418","author":"Klausz","year":"2015","journal-title":"J. Immunol. Methods"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jim.2011.06.023","article-title":"Human kappa light chain targeted Pseudomonas exotoxin A\u2014Identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development","volume":"371","author":"Kellner","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/1078-0432.CCR-08-1456","article-title":"CAT-8015: A second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies","volume":"15","author":"Alderson","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.molonc.2016.07.003","article-title":"Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy","volume":"10","author":"Bauss","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2008.20.2630","article-title":"Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia","volume":"27","author":"Kreitman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Fleming, B.D., and Ho, M. (2020). Development of Glypican-3 targeting immunotoxins for the treatment of liver cancer: An update. Biomolecules., 10.","DOI":"10.3390\/biom10060934"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1200\/JCO.2005.11.437","article-title":"Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies","volume":"23","author":"Kreitman","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies","volume":"18","author":"Kreitman","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_165","first-page":"2808","article-title":"Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40)","volume":"51","author":"Pai","year":"1991","journal-title":"Cancer Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nm0396-350","article-title":"Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to Pseudomonas exotoxin","volume":"2","author":"Pai","year":"1996","journal-title":"Nat. Med."},{"key":"ref_167","first-page":"3092","article-title":"A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors","volume":"8","author":"Posey","year":"2002","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_168","first-page":"2157","article-title":"Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma","volume":"6","author":"Rand","year":"2000","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF02700027","article-title":"Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma","volume":"64","author":"Weber","year":"2003","journal-title":"J. Neuro-Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/01.cji.0000162782.86008.mL","article-title":"Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor","volume":"28","author":"Garland","year":"2005","journal-title":"J. Immunother."},{"key":"ref_171","first-page":"2311","article-title":"Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor","volume":"5","author":"Villa","year":"1999","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/B:BREA.0000004371.48757.19","article-title":"Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2\/HER2","volume":"82","author":"Azemar","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"R617","DOI":"10.1186\/bcr1264","article-title":"Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2\/HER2 receptor in patients with advanced solid malignomas","volume":"7","author":"Harder","year":"2005","journal-title":"Breast Cancer Res. BCR"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1026290315809","article-title":"Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors","volume":"65","author":"Sampson","year":"2003","journal-title":"J. Neuro-Oncol."},{"key":"ref_175","first-page":"57","article-title":"Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer","volume":"1","author":"Goldberg","year":"1995","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1242\/jcs.107.9.2599","article-title":"The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans","volume":"107","author":"Mesri","year":"1994","journal-title":"J. Cell Sci."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"107759","DOI":"10.1016\/j.intimp.2021.107759","article-title":"Recent development and optimization of Pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications","volume":"96","author":"Wu","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/1078-0432.CCR-19-2586","article-title":"Phase I\/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma","volume":"26","author":"Alewine","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1158\/1078-0432.CCR-11-0493","article-title":"Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts","volume":"17","author":"Mossoba","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_180","first-page":"176","article-title":"VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer","volume":"10","author":"Biggers","year":"2008","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/bi9520848","article-title":"Crystal Structure of Diphtheria Toxin Bound to Nicotinamide Adenine Dinucleotide","volume":"35","author":"Bell","year":"1996","journal-title":"Biochemistry"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/357216a0","article-title":"The crystal structure of diphtheria toxin","volume":"357","author":"Choe","year":"1992","journal-title":"Nature"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1021\/bi962214s","article-title":"Crystal structure of nucleotide-free diphtheria toxin","volume":"36","author":"Bell","year":"1997","journal-title":"Biochemistry"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/pro.5560030912","article-title":"Refined structure of monomelic diphtheria toxin at 2.3 \u00c5 resolution","volume":"3","author":"Bennett","year":"1994","journal-title":"Protein Sci."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.drudis.2008.06.017","article-title":"Targeted therapy of cancer using diphtheria toxin-derived immunotoxins","volume":"13","author":"Potala","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.canlet.2008.09.025","article-title":"Enhanced interleukin-2 diphtheria toxin conjugate-induced growth suppression in retinoic acid-treated hypoxic hepatocellular carcinoma cells","volume":"274","author":"Kim","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jdcr.2017.06.031","article-title":"Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox","volume":"3","author":"Lewis","year":"2017","journal-title":"JAAD Case Rep."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.cji.0000175468.19742.10","article-title":"Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients with Melanoma","volume":"28","author":"Attia","year":"2005","journal-title":"J. Immunother."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1073\/pnas.1815087116","article-title":"Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma","volume":"116","author":"Cheung","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0959-8049(14)70179-0","article-title":"53 Adeno-associated virus (AAV) carrying diphtheria toxin a gene for pancreatic cancer therapy","volume":"50","author":"Chen","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1006\/mthe.2002.0694","article-title":"Regulated expression of diphtheria toxin in prostate cancer cells","volume":"6","author":"Peng","year":"2002","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0002-9378(97)70149-2","article-title":"In vitro expression of the diphtheria toxin A-chain gene under the control of human chorionic gonadotropin gene promoters as a means of directing toxicity to ovarian cancer cell lines","volume":"177","author":"Lidor","year":"1997","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"7343","DOI":"10.1128\/JVI.76.14.7343-7348.2002","article-title":"PG13 packaging cells produce recombinant retroviruses carrying a diphtheria toxin mutant which kills cancer cells","volume":"76","author":"Qiao","year":"2002","journal-title":"J. Virol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2019.12.015","article-title":"Spatiotemporally controllable diphtheria toxin expression using a light-switchable transgene system combining multifunctional nanoparticle delivery system for targeted melanoma therapy","volume":"319","author":"He","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1479-5876-7-69","article-title":"Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences","volume":"7","author":"Mizrahi","year":"2009","journal-title":"J. Transl. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"178174","DOI":"10.1155\/2010\/178174","article-title":"Use of H19 Gene Regulatory Sequences in DNA-Based Therapy for Pancreatic Cancer","volume":"2010","author":"Scaiewicz","year":"2010","journal-title":"J. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Hasenpusch, G., Pfeifer, C., Aneja, M.K., Wagner, K., Reinhardt, D., Gilon, M., Ohana, P., Hochberg, A., and Rudolph, C. (2011). Aerosolized BC-819 inhibits primary but not secondary lung cancer growth. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020760"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.juro.2013.12.011","article-title":"DNA based therapy with diphtheria toxin-A BC-819: A phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer","volume":"191","author":"Gofrit","year":"2014","journal-title":"J. Urol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jconrel.2018.01.031","article-title":"Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs","volume":"274","author":"Serna","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2021.05.014","article-title":"Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4","volume":"335","author":"Serna","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1091-255X(01)00040-3","article-title":"Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer","volume":"6","author":"Hotz","year":"2002","journal-title":"J. Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.toxicon.2019.09.006","article-title":"Peptides derived from a short stretch of diphtheria toxin bind to heparin-binding epidermal growth factor-like growth factor","volume":"169","author":"Agarwal","year":"2019","journal-title":"Toxicon"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/12\/3836\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:31:37Z","timestamp":1760139097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/12\/3836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":202,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["molecules27123836"],"URL":"https:\/\/doi.org\/10.3390\/molecules27123836","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]}}}